TRCT
MGX icon

Tower Research Capital (TRC)’s Metagenomi Therapeutics MGX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56 Sell
42
-9,261
-100% -$14.4K ﹤0.01% 5028
2025
Q4 		$15.1K Buy
+9,303
New +$20.1K ﹤0.01% 3309
2025
Q3 		– Sell
-12,375
Closed -$18.3K – 5692
2025
Q2 		$18.3K Buy
12,375
+2,880
+30% +$4.51K ﹤0.01% 3736
2025
Q1 		$12.9K Buy
9,495
+5,623
+145% +$13.4K ﹤0.01% 3415
2024
Q4 		$14K Sell
3,872
-1,375
-26% -$3.32K ﹤0.01% 3487
2024
Q3 		$11.4K Buy
5,247
+872
+20% +$3.02K ﹤0.01% 3668
2024
Q2 		$17.9K Buy
4,375
+3,919
+859% +$26.9K ﹤0.01% 3814
2024
Q1 		$4.81K Buy
+456
New +$5.24K ﹤0.01% 4624

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tower Research Capital (TRC)'s MGX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Metagenomi Therapeutics (MGX) stake by 100% in Q1 2026, selling an estimated $14.4K and leaving 42 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #5028.

Tower Research Capital (TRC) first reported a position in MGX in Q1 2024 and has held it in 8 quarters since. The position peaked at $18.3K in Q2 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Tower Research Capital (TRC) held 42 shares of Metagenomi Therapeutics worth $56 as of Q1 2026.
  • Tower Research Capital (TRC) sold 9,261 Metagenomi Therapeutics shares in Q1 2026, an estimated $14.4K.
  • Metagenomi Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5028 holding.
  • Tower Research Capital (TRC) first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Tower Research Capital (TRC)'s Metagenomi Therapeutics position peaked at $18.3K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.